Adamis Pharmaceuticals (ADMP) Issues Letter to Stockholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- Wall Street ends sharply higher, lifted by soaring Microsoft
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Adamis Pharmaceuticals Issues Letter to Stockholders
July 21, 2022 7:30 AM EDTSAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief Executive Officer David J. Marguglio.
ADAMIS HAS NEW LEADERSHIP COMMITTED TO ENHANCING SHAREHOLDER VALUE
YOUR SUPPORT AT THE ANNUAL MEETING IS CRITICAL TO OUR FUTURE... More
